Molecular Partners AG Sponsored ADR

MOLN

Healthcare Biotechnology

Molecular Partners AG Sponsored ADR’s revenue for fiscal 2024 (year ended December 2024) was $5.6 million, down 28.0% from fiscal 2023.

Revenue
−98.9%
EPS
+8.27%
Free cash flow
+11.1%

Quarter to September 2026, against a year earlier

3.22 0.03 −0.92%
Market cap
$119.2M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
2/9
ROIC
0.00%
Net debt / EBITDA
1.7×
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
6.46 7.27 9.42 8.79
Net Debt/EBITDA
4.95 5.18 6.09 7.20
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.32) (0.35) (0.48) (0.32)
Book value per Share
1.63 1.91 2.33 2.60
Free Cash Flow
(12.08) (13.53) (18.18) (11.90)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026